ImmuneOncia Therapeutics
Korea - YonginBiotechnology
Focus: ImmuneOncia Therapeutics is a Korea-based biotechnology company specializing in immunotherapy monoclonal antibodies. Limited public data constrains assessment of market position and scale.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Open Jobs
0
About ImmuneOncia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow ImmuneOncia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IMC-001
Solid TumorClinical Trials (1)
NCT03644056Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
Phase 1Help build intelligence for ImmuneOncia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.